🇺🇸 FDA
Patent

US 8188283

Modulators of cystic fibrosis transmembrane conductance regulator

granted A61KA61K31/4375A61P

Quick answer

US patent 8188283 (Modulators of cystic fibrosis transmembrane conductance regulator) held by Vertex Pharmaceuticals Incorporated expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/4375, A61P, A61P11/00, A61P13/12